相似文献
1
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.
J Cyst Fibros. 2011 Dec;10(6):453-9. doi: 10.1016/j.jcf.2011.07.003. Epub 2011 Jul 30.
2
Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.
J Cyst Fibros. 2010 Sep;9(5):332-8. doi: 10.1016/j.jcf.2010.05.004. Epub 2010 Jun 19.
3
Antibiotic duration and changes in FEV are not associated with time until next exacerbation in adult cystic fibrosis: a single center study.
BMC Pulm Med. 2017 Nov 29;17(1):160. doi: 10.1186/s12890-017-0503-6.
4
Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Pediatr Pulmonol. 2013 Jul;48(7):649-57. doi: 10.1002/ppul.22658. Epub 2012 Sep 4.
5
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.
Eur Respir J. 2012 Jul;40(1):61-6. doi: 10.1183/09031936.00159111. Epub 2011 Dec 1.
6
Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Pediatr Pulmonol. 2015 May;50(5):431-40. doi: 10.1002/ppul.23147. Epub 2014 Dec 19.
7
Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
J Cyst Fibros. 2015 May;14(3):334-40. doi: 10.1016/j.jcf.2014.10.002. Epub 2014 Oct 23.
8
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA. 2010 May 5;303(17):1707-15. doi: 10.1001/jama.2010.563.
9
Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
J Cyst Fibros. 2012 Jan;11(1):8-13. doi: 10.1016/j.jcf.2011.07.008. Epub 2011 Aug 16.
10
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
Thorax. 2011 Aug;66(8):680-5. doi: 10.1136/thx.2011.161117. Epub 2011 Jun 15.
引用本文的文献
1
Diagnosis and Management of Cystic Fibrosis Exacerbations.
Semin Respir Crit Care Med. 2023 Apr;44(2):225-241. doi: 10.1055/s-0042-1760250. Epub 2023 Feb 6.
2
A new path for CF clinical trials through the use of historical controls.
J Cyst Fibros. 2022 Mar;21(2):293-299. doi: 10.1016/j.jcf.2021.11.007. Epub 2021 Dec 5.
3
Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.
Thorax. 2022 May;77(5):461-469. doi: 10.1136/thoraxjnl-2021-217594. Epub 2021 Sep 23.
4
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.
J Cyst Fibros. 2021 Nov;20(6):1026-1034. doi: 10.1016/j.jcf.2021.08.007. Epub 2021 Sep 17.
5
Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.
Antibiotics (Basel). 2021 Apr 23;10(5):486. doi: 10.3390/antibiotics10050486.
6
Epidemiologic Study of Cystic Fibrosis: 25 years of observational research.
Pediatr Pulmonol. 2021 May;56(5):823-836. doi: 10.1002/ppul.25248. Epub 2021 Jan 12.
7
Acute Pulmonary Exacerbations in Cystic Fibrosis.
Semin Respir Crit Care Med. 2019 Dec;40(6):792-803. doi: 10.1055/s-0039-1697975. Epub 2019 Oct 28.
8
Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial.
Am J Respir Crit Care Med. 2018 Sep 1;198(5):639-647. doi: 10.1164/rccm.201801-0105OC.
9
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
Curr Opin Pulm Med. 2017 Nov;23(6):530-535. doi: 10.1097/MCP.0000000000000418.
10
C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.
J Pulm Respir Med. 2016 Oct 14;6(5):1000375. doi: 10.4172/2161-105X.1000375.
本文引用的文献
1
Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis.
J Cyst Fibros. 2010 Dec;9(6):419-24. doi: 10.1016/j.jcf.2010.08.008.
2
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatr Pulmonol. 2010 Feb;45(2):127-34. doi: 10.1002/ppul.21117.
3
Healthcare expenditures for privately insured people with cystic fibrosis.
Pediatr Pulmonol. 2009 Oct;44(10):989-96. doi: 10.1002/ppul.21090.
4
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3.
5
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8. doi: 10.1164/rccm.200712-1804OC. Epub 2008 Jul 24.
6
Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005.
Pediatr Pulmonol. 2008 Aug;43(8):739-44. doi: 10.1002/ppul.20830.
7
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.
Thorax. 2007 Apr;62(4):360-7. doi: 10.1136/thx.2006.060889.
8
Cystic fibrosis pulmonary exacerbations.
J Pediatr. 2006 Feb;148(2):259-64. doi: 10.1016/j.jpeds.2005.10.019.
9
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
N Engl J Med. 2006 Jan 19;354(3):229-40. doi: 10.1056/NEJMoa043900.
10
Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis.
Chest. 2005 Oct;128(4):2347-54. doi: 10.1378/chest.128.4.2347.
Zotero 插件